Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.33 |
| ▸ | CNR2 | P34972 | 10/20 | 0.33 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143518 | 0.93 | CNR2 (0.39) | CNR1CNR2GPR18GPR55HSP90AA1 | |
| SCHEMBL5668740 | 0.90 | CNR2 (0.41) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL224924 | 0.88 | CNR1 (0.38) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL769153 | 0.87 | CNR1 (0.36) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL7147637 | 0.87 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL10484223 | 0.87 | CNR2 (0.37) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL7787052 | 0.86 | CNR1 (0.34) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL5648044 | 0.86 | CNR2 (0.36) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL5834169 | 0.85 | CNR1 (0.37) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL5648165 | 0.85 | CNR2 (0.37) | CNR1CNR2GPR18GPR55NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515051-B2 | Stability and durability and a low loss rate when incorporated into automotive coatings; soluble in a variety of substrates including thermoplastic polymers and often are colorless | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6458872-B1 | FOR USE IN AUTOMOTIVE COATINGS, THERMOPLASTIC FORMULATIONS | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-10-01 | — | — | US | disclosed |
| US-20020099221-A1 | Benzotriazole UV absorbers having enhanced durability | RAVICHANDRAN RAMANATHAN (US) | 2002-07-25 | — | — | US | disclosed |
| US-20020065341-A1 | Benzotriazole UV absorbers having enhanced durability | RAVICHANDRAN RAMANATHAN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6262151-B1 | FOR AUTOMOTIVE COATINGS | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-20010007886-A1 | Benzotriazole UV absorbers having enhanced durability | RAVICHANDRAN RAMANATHAN (US) | 2001-07-12 | — | — | US | disclosed |
| US-6166218-A | Benzotriazole UV absorbers having enhanced durability | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-5977219-A | Benzotriazole UV absorbers having enhanced durability | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099221-A1 | Benzotriazole UV absorbers having enhanced durability | TERT, AHR, ARNT | CNR1 2980/4885CNR2 2562/4885GPR18 2527/4885 |
| US-20020065341-A1 | Benzotriazole UV absorbers having enhanced durability | TERT, AHR, ARNT | CNR1 2980/4885CNR2 2562/4885GPR18 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.